<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Chemotherapy for elderly patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) results in a median overall survival (OS) of ≤ 1 year </plain></SENT>
<SENT sid="1" pm="."><plain>Elderly patients often present with cardiac comorbidity </plain></SENT>
<SENT sid="2" pm="."><plain>Gemtuzumab ozogamicin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>) is active in elderly (≥ 60 years) patients with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with low cardiac toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: This randomized phase II study compared a standard combination of ara-C and <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> (DNR; 7+3) versus ara-C plus gemtuzumab ozogamicin (7+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>) as the first course of induction therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Primary objectives were comparison of blast clearance on day 16, event-free survival (EFS), and remission duration </plain></SENT>
<SENT sid="5" pm="."><plain>OS, complete remission (CR), and tolerability were secondary objectives </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: One hundred and nineteen patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:e sem="disease" ids="C1336735" disease_type="Neoplastic Process" abbrv="">treatment-related AML</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with a history of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), or high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> entered the study </plain></SENT>
<SENT sid="7" pm="."><plain>Median age of 115 patients (intent-to-treat population) was 69 years </plain></SENT>
<SENT sid="8" pm="."><plain>Protocol outlined a second course 7+3 for patients without blast clearance and two courses of high-dose ara-C consolidation upon CR </plain></SENT>
<SENT sid="9" pm="."><plain>Both treatments were equally effective in blast clearance, CR, EFS, remission duration, or OS (median: 7+3, 9 months; 7+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>, 10 months) </plain></SENT>
<SENT sid="10" pm="."><plain>Induction <z:hpo ids='HP_0011420'>death</z:hpo> rate was higher in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> group due to <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The study did not show significant superiority of 7+<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> over standard 7+3 </plain></SENT>
</text></document>